3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
NIH
2
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Ovarian Neoplasms
7
Uterine Cervical Neoplasms
2
Rectal Neoplasms
2
Endometrial Neoplasms
2
Uveal Melanoma
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Pleural Effusion, Malignant
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Leiomyosarcoma
1
Gliosarcoma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinosarcoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Brain Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
2
pazopanib
2
Sunitinib
2
Radiotherapy
2
selinexor
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
ixazomib
1
cediranib
1
Zoledronic Acid
1
Radiotherapy, Intensity-Modulated
1
Radiation Dose Hypofractionation
1
Polymerase Chain Reaction
1
Nivolumab
1
Neoadjuvant Therapy
1
Methotrexate
1
Ifosfamide
1
Gene Expression Profiling
1
Gemcitabine
1
Epirubicin
1
Doxorubicin
1
Diathermy
1
Dasatinib
1
Dactinomycin
1
Dacarbazine
1
Cisplatin
1
Blotting, Western
1
Axitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Sarcoma, Alveolar Soft Part
×
cediranib
×
Clear all
NCT01337401
2019-01-24
CASPS
Institute of Cancer Research, United Kingdom
Phase 2
Unknown
36 enrolled